** charts before earnings **
** charts after earnings **
Quest Diagnostics reports EPS in-line, misses on revs; lowers FY18 guidance
|
|
- Reports Q3 (Sep) earnings of $1.68 per share, in-line with the S&P Capital IQ Consensus of $1.68; revenues rose 1.8% year/year to $1.89 bln vs the $1.95 bln S&P Capital IQ Consensus.
- Co updates guidance for FY18, sees EPS of $6.53-6.60 (Prior $6.53-6.67), excluding non-recurring items, vs. $6.60 S&P Capital IQ Consensus; sees FY18 revs of ~$7.62 bln (Prior $7.7-7.74 bln) vs. $7.71 bln S&P Capital IQ Consensus.
- "We had a productive quarter, announcing three acquisitions and a Professional Lab Services agreement. We are updating our full-year revenue guidance to reflect lower than expected revenue performance this year, which has been affected in large part by industry headwinds we called out in the previous quarter. Looking ahead, our acquisition pipeline, along with our expanding health plan access, including UnitedHealthcare beginning January 1, position us well for growth in 2019."
|
No comments:
Post a Comment